Novo Nordisk FDA Setback Creates Opportunity for Korean CDMOs

Novo Nordisk has faced severe FDA sanctions and approval setbacks for its U.S. production facilities due to quality control failures, disrupting drug approval timelines and opening opportunities for Korean biotech Contract Development and Manufacturing Organizations (CDMOs) expanding in the U.S. These Korean companies, including Celltrion, Samsung Biologics, and Lotte Biologics, are strategically acquiring and expanding U.S. production sites to capitalize on growing demand and regulatory risks affecting big pharma.

This Wire brief sits within Fusion42's coverage of Biotech.